The value of defining molecular resistance in patients with progressive EGFR and ALK-driven lung cancer in a public system.

3126Background: Repeat molecular profiling, except to detect EGFR T790M, is not routinely performed in Canadian patients with lung cancer progressing on EGFR tyrosine kinase inhibitors (TKIs). We p...